Allena Pharmaceuticals has started the Phase IIb dose-ranging study of ALLN-177 for secondary hyperoxaluria.

ALLN-177 is an orally administered recombinant oxalate-degrading enzyme being developed for the chronic management of hyperoxaluria and kidney stones (nephrolithiasis).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hyperoxaluria is a condition that results from high oxalate levels in the urine due to either hyper-absorption of oxalate from the diet (secondary) or from overproduction of oxalate by the liver (primary) due to a genetic defect.

The Phase IIb randomised and crossover study has been designed to assess the safety, tolerability, and efficacy of three different doses of ALLN-177 to reduce urinary oxalate excretion in patients with secondary hyperoxaluria.

"Our Phase I and Phase IIa study results highlight the potential of ALLN-177 to help patients with oxalate disorders."

Allena Pharmaceuticals COO Dr Louis Brenner said: "Allena has made significant recent progress with the advancement of our ALLN-177 clinical programme and with the addition of Dr Annamaria Kausz to our management team.

"Our Phase I and Phase IIa study results highlight the potential of ALLN-177 to help patients with oxalate disorders, and we are fortunate to secure Annamaria’s leadership for our clinical development organisation."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Allena, earlier completed studies, including Phase I trial in healthy volunteers and Phase IIa trial in patients with secondary hyperoxaluria, have showed proof-of-concept for the reduction of urinary oxalate excretion using ALLN-177.

ALLN-177 is said to target oxalate in the gastrointestinal tract that will help to reduce the burden of both dietary and endogenously produced oxalate.

It holds the capability to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as reduce the incidence of calcium oxalate related complications.